Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 10 - 06 symbols : SNYNF save search
BioNTech and Australia’s State of Victoria Form Strategic Partnership to Establish mRNA Research Center and Manufacturing Facility
Published: 2022-10-06 (Crawled : 00:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -4.81%
H: 0.0%
C: -2.52%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.46%
H: 0.0%
C: 0.0%
BNTX | News | $88.01 1.38% 1.36% 390K
|
Health Technology
|
| O: -0.79%
H: 1.14%
C: -1.28%
partnership research state mrna
Autoimmune Hemolytic Anemia Therapeutics Market to Record a CAGR of 9.1%, Majority of Market Growth to Originate from North America - Technavio
Published: 2022-10-06 (Crawled : 23:00) - prnewswire.com
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
|
| O: -3.32%
H: 0.0%
C: 0.0%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -4.81%
H: 0.0%
C: -2.52%
AZNCF | News | $136.2 -4.19% 1.7K
|
Health Technology
|
| O: 0.07%
H: 0.92%
C: 0.27%
VTRS | News A | $11.235 -0.13% -0.13% 5.1M
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: -1.8%
BAX | $40.4 2.36% 0.0% 3.2M
|
Health Technology
|
| O: -0.64%
H: 0.45%
C: -0.48%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.46%
H: 0.0%
C: 0.0%
AZN | News | $70.12 2.29% 2.24% 4.8M
|
Health Technology
|
| O: 1.55%
H: 0.79%
C: -0.65%
ARGX | $369.01 2.44% 2.38% 320K
|
Health Technology
|
| O: -3.19%
H: 0.91%
C: -0.99%
america anemia therapeutics growth market
Global Nanomedicine Market to Reach $433.9 Billion by 2027 at a 13.46% CAGR
Published: 2022-10-06 (Crawled : 20:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -4.81%
H: 0.0%
C: -2.52%
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -4.56%
H: 0.29%
C: 0.29%
NVS | News | $95.12 0.81% -1.18% 2.4M
|
Health Technology
|
| O: 0.16%
H: 0.09%
C: -0.67%
GE | News | $150.19 1.44% -0.13% 7M
|
Electronic Technology
|
| O: -0.92%
H: 0.25%
C: -1.6%
ABT | News | $107.07 -0.2% 0.0% 4.9M
|
Health Technology
|
| O: 0.05%
H: 2.53%
C: -0.69%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.46%
H: 0.0%
C: 0.0%
global market
Lilly's Mounjaro is on the Fast Track Toward Potential Obesity Approval
Published: 2022-10-06 (Crawled : 16:00) - biospace.com/
MS | News 0 d | $92.09 1.58% 0.01% 7.3M
|
Finance
|
| O: -0.8%
H: 0.9%
C: -1.38%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -1.63%
H: 0.0%
C: 0.0%
obesity approval potential
Anticipating FDA "Yes", Provention Inks Co-Promotion Deal with Sanofi for T1D Drug
Published: 2022-10-06 (Crawled : 16:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -1.63%
H: 0.0%
C: 0.0%
fda drug deal sanofi
Anticipating FDA "Yes", Provention Inks Co-Promotion Deal with Sanofi for T1D...
Published: 2022-10-06 (Crawled : 15:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -1.63%
H: 0.0%
C: 0.0%
fda deal sanofi
Anticoagulants Market is expected to generate a revenue of USD 56.16 Billion by 2028, Globally, at 10.20% CAGR: Verified Market Research®
Published: 2022-10-06 (Crawled : 14:20) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -2.53%
H: 0.0%
C: 0.0%
PFE | News A | $26.26 1.0% -0.08% 36M
|
Health Technology
|
| O: -0.82%
H: 0.03%
C: -1.53%
JNJ | News | $149.12 0.82% 0.0% 9.3M
|
Health Technology
|
| O: -0.3%
H: 0.0%
C: 0.0%
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: -1.25%
H: 0.53%
C: -0.1%
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: -0.92%
H: 0.06%
C: -0.78%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -1.63%
H: 0.0%
C: 0.0%
research expected market
Framework Solutions Launches Medical Affairs Division with Appointment of Key Executive
Published: 2022-10-06 (Crawled : 13:00) - prnewswire.com
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -1.63%
H: 0.0%
C: 0.0%
solutions
Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals
Published: 2022-10-06 (Crawled : 12:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -1.63%
H: 0.0%
C: 0.0%
PRVB | $24.98 0.08% 9.1M
|
Health Technology
|
| O: 24.09%
H: 0.0%
C: 0.0%
teplizumab diabetes potential sanofi
Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes
Published: 2022-10-06 (Crawled : 12:00) - prnewswire.com
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -1.63%
H: 0.0%
C: 0.0%
PRVB | $24.98 0.08% 9.1M
|
Health Technology
|
| O: 24.09%
H: 0.0%
C: 0.0%
diabetes agreement therapy sanofi
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.